This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koul, D. Articles by Yung, W.K. A. Search for Related Content PubMed PubMed Citation Articles by Koul, D. Articles by Yung, W.K. A.

¹ Brain Tumor Center, Department of Neuro-Oncology and ² Department of Molecular Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Dimpy Koul, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 1002, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-834-6202; Fax: 713-834-6230. E-mail: Dkoul{at}mdanderson.org.

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and Akt are important regulators of the phosphatidylinositol 3-kinase (PI3K) pathway and thus are important to the regulation of a wide spectrum of tumor-related biological processes. Akt regulates several critical cellular functions, including cell cycle progression; cell migration, invasion, and survival; and angiogenesis. Decreased expression of PTEN and overexpression of the Akt proto-oncogene, which is located downstream of PI3K, have been shown in a variety of cancers, including glioblastoma. Novel small-molecule inhibitors of receptors and signaling pathways, including inhibitors of the PI3K pathway, have shown antitumor activity, but inhibitors of Akt have not been examined. In this study, we tested our hypothesis that the pharmacologic inhibition of Akt has an antiproliferative effect on gliomas. We showed that two newly developed Akt inhibitors, KP-372-1 and KP-372-2 (herein called KP-1 and KP-2), effectively inhibited the PI3K/Akt signaling cascade. KP-1 and KP-2 blocked both the basal and epidermal growth factor–induced phosphorylation of Akt Ser⁴⁷³ at 125 and 250 nmol/L, which, in turn, reduced the activation of intracellular downstream targets of Akt, including GSK-3ß and p70s6k. Furthermore, the treatment of U87 and U251 glioma cells with 125 to 250 nmol/L KP-1 and KP2 for 48 hours inhibited cell growth by 50%. This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas. [Mol Cancer Ther 2006;5(3):637–44]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: The current address for S. Shishodia is Department of Biology, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004.

³ QLT, Inc., personal communication.

Received 11/ 1/05; revised 12/14/05; accepted 1/10/06.

This article has been cited by other articles:

				A. L. Howes, G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures Mol. Cancer Ther., September 1, 2007; 6(9): 2505 - 2514. [Abstract] [Full Text] [PDF]

				A. B. Hjelmeland, K. P. Lattimore, B. E. Fee, Q. Shi, S. Wickman, S. T. Keir, M. D. Hjelmeland, D. Batt, D. D. Bigner, H. S. Friedman, et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion Mol. Cancer Ther., September 1, 2007; 6(9): 2449 - 2457. [Abstract] [Full Text] [PDF]